Plain-English translation of NCT06142474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether two medications called empagliflozin or dapagliflozin can help people with acute heart failure who are on a ventilator. Researchers want to see if starting this medication a few days before the patient is taken off breathing support helps reduce heart strain and makes the weaning process safer and more successful.
When patients with severe heart failure are taken off ventilators, their hearts can become stressed and sometimes fail again. Researchers believe this newer class of medication might protect the heart during this critical transition and help patients recover better.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to either receive the medication or standard care only. If you get the medication, you'll start it 3 days before doctors begin weaning you off the ventilator. You'll have heart ultrasounds, chest X-rays, blood tests, and heart rhythm tracings at several points: before weaning starts, during the weaning process, within 24 hours after extubation, at 1–2 weeks, and at 3 months. The study will follow you for about 3 months total.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Taiwan
Phase
Large-scale testing
Sponsor
National Taiwan University Hospital
Enrollment target
~450 participants
Started
October 2022
Primary completion
October 2030
Age range
20 Years and older
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chih Fan Yeh
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.